Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
The objective of the video article is to present a complete robotic restaging surgery for an early stage endometrioid ovarian cancer developed in an endometrioma in a young patient wishing to preserve her fertility. We demonstrate the entire surgical technique of restaging. Institutional review board approval was not required for this video presentation.
We present the case of a 27-year-old patient with one child and no medical history who was treated in emergency for a right adnexal torsion by laparoscopy. A cystectomy was performed with perioperative rupture of the cyst. The analysis of the surgical specimen led to the diagnosis of grade 1 endometrioid ovarian cancer developed within an endometrioma.
The patient underwent a complete surgical staging including pelvic and para-aortic lymph node dissections, appendectomy, omentectomy and right salpingo-oophorectomy by robot-assisted laparoscopy.
All specimens were negative at final pathology examination and the disease was confirmed at stage 1C1 (peroperative spillage). There were no surgical complications. No adjuvant treatment was indicated. The patient was pregnant 2 months after the surgery.
Fertility-sparing minimally invasive surgery is acceptable for women of childbearing age who want to become pregnant in the case of early-stage ovarian cancer, after adequate staging. Minimally invasive surgery is safe,1 effective, and particularly adapted for women who wish to preserve their fertility without compromising oncological outcomes. This option may be safely proposed for 1A and 1C1, low-grade serous or endometrioid ovarian cancer.2 3 Complete information about oncological and obstetrical outcomes is mandatory and patients should agree to comply with close follow-up.4
In conclusion, minimally invasive fertility-sparing surgery is safe and effective for women with early-stage ovarian cancer.
Data availability statement
There are no data in this work.
Patient consent for publication
Contributors Conception and design of study: HA, MK, A-SB. Data collection: HA, EB, MK. Data analysis and interpretation: HA, MK, H-TN-X, EB. Responsible surgeon or imager: HA, EB, GA. Manuscript preparation: HA, MK, EB. Patient recruitment: HA, A-SB.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.